Can the BCG vaccine prevent TB? 

The Bacillus Calmette-Guérin vaccine, commonly known as the BCG, is currently the only licensed vaccination available to help protect against tuberculosis. While it was once a routine part of the school vaccination programme in the United Kingdom, its use is now targeted towards specific groups who are at a higher risk of exposure to the bacteria. The vaccine works by introducing a weakened form of the bacteria to stimulate the immune system, providing a level of protection that can last for many years. However, its effectiveness varies significantly depending on the age of the recipient and the specific form of the disease being prevented, making it one of several tools used in the national strategy to control the spread of infection. 

What We’ll Discuss in This Article 

• The specific types of tuberculosis the BCG vaccine is most effective against. 

• The current NHS eligibility criteria for infants and adults in the UK. 

• The role of the Mantoux skin test before receiving the vaccination. 

• Why the BCG is no longer part of the routine childhood schedule. 

• Common side effects and the normal healing process of the injection site. 

• The limitations of the vaccine in preventing adult pulmonary tuberculosis. 

Understanding the effectiveness of the BCG vaccine 

The BCG vaccine provides varying levels of protection depending on the age of the person and the part of the body affected by the bacteria. The BCG vaccine is 70 to 80 percent effective against the most severe forms of TB, such as TB meningitis in children. This high level of protection in infants makes it a vital tool for preventing life-threatening complications that can occur when the bacteria spread to the brain or the blood. However, the vaccine is notably less effective at preventing pulmonary tuberculosis, which is the most common form of the disease that affects the lungs in adults. Because it does not consistently prevent the initial infection or the transmission of the bacteria between adults, it is not used as a primary method for stopping the overall spread of TB in the general population. 

Who is eligible for the BCG vaccine in the UK? 

In the United Kingdom, the BCG vaccine is not routinely offered to all children but is reserved for those at an increased risk of coming into contact with tuberculosis. BCG vaccination is recommended for newborn babies who live in areas where TB rates are high or who have parents or grandparents from a country where TB is widespread. This targeted approach ensures that those most vulnerable to severe childhood forms of the disease are protected. Additionally, the vaccine may be offered to unvaccinated people under the age of 16 who are going to live or work in high-risk countries for more than three months, as well as certain occupational groups, such as healthcare workers and laboratory staff, who are likely to be exposed to the bacteria through their work. 

The role of the Mantoux test before vaccination 

For many older children and adults, a skin test known as the Mantoux test is a mandatory step before the BCG vaccine can be administered. This test determines whether the individual has already been exposed to tuberculosis or has a pre-existing immune response. The Mantoux test involves a small injection into the forearm and is checked by a clinician two to three days later. If the test shows a significant reaction (a positive result), it indicates that the person may already have a latent or active infection, and receiving the BCG vaccine would be unnecessary and potentially cause a severe local reaction. In these cases, the individual is usually referred for further investigation, such as a chest X-ray, rather than receiving the vaccination. 

Why the BCG is no longer a routine school vaccine 

The UK moved away from a universal school-based BCG programme in 2005 due to the changing epidemiology of the disease. As the overall rates of tuberculosis in the general population fell to very low levels, the benefit of vaccinating every teenager was significantly reduced. Public health data showed that the vast majority of new cases were concentrated in specific high-risk groups rather than the wider community. By switching to a targeted neonatal programme, the NHS can focus resources on protecting infants in high-risk environments where the vaccine is most effective. This strategy aligns with international World Health Organization (WHO) recommendations for countries with a low incidence of tuberculosis, focusing on prevention where the clinical need is greatest. 

Managing side effects and the injection site 

The BCG vaccine is unique in the way it heals, often leaving a small, permanent scar on the upper arm. Immediately after the injection, a raised blister usually appears, followed by a small spot that may become sore and ulcerate over several weeks. This is a normal part of the immune system’s response and can take several months to heal completely. It is important not to cover the site with an airtight plaster, although a dry dressing can be used if there is any weeping. More serious side effects, such as an abscess at the injection site or a severe allergic reaction, are extremely rare. Parents are advised to keep the area clean and seek medical advice only if the sore becomes significantly infected or fails to show signs of healing after several months. 

Conclusion 

The BCG vaccine is a highly effective tool for protecting infants against the most severe and life-threatening forms of tuberculosis, such as meningitis. While it is no longer given routinely to all schoolchildren, it remains a critical intervention for those in high-risk groups or specific occupations. Its primary limitation is its variable effectiveness in preventing the common lung-based form of TB in adults, which is why UK health policy emphasizes targeted vaccination alongside early diagnosis and treatment. 

If you experience severe, sudden, or worsening symptoms, such as a severe allergic reaction or sudden difficulty breathing after a vaccination, call 999 immediately. 

Authority Snapshot (E-E-A-T Block) 

This article provides a clinical overview of the BCG vaccination programme in the United Kingdom, focusing on its role in tuberculosis prevention. The information is strictly aligned with the evidence-based guidelines provided by the NHS, NICE, and the UK Health Security Agency. The content has been authored by a medical content team and reviewed by Dr. Stefan Petrov, an MBBS-qualified UK physician, to ensure clinical accuracy and adherence to safety protocols.